These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 8466073)
1. High-dose droperidol protects against experimental coronary thrombosis in dogs and pigs and attenuates aggregation of porcine platelets and Ca2+ mobilization in human platelets. Bertha BG; Sill JC; Berger I; Folts JD; Milde JH Anesthesiology; 1993 Apr; 78(4):733-43. PubMed ID: 8466073 [TBL] [Abstract][Full Text] [Related]
2. Human platelet Ca2+ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone. Sill JC; Bertha B; Berger I; Uhl C; Nugent M; Folts J Circulation; 1997 Sep; 96(5):1647-53. PubMed ID: 9315560 [TBL] [Abstract][Full Text] [Related]
3. Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries. Qureshi AA; Karpen CW; Qureshi N; Papasian CJ; Morrison DC; Folts JD Lipids Health Dis; 2011 Apr; 10():58. PubMed ID: 21489303 [TBL] [Abstract][Full Text] [Related]
4. Clinically relevant concentrations of dopamine do not amplify agonist-induced human platelet Ca2+ mobilization or GP IIb IIIa activation and do not accelerate acute coronary thrombosis in dogs. Sill JC; Bertha B; Berger I; Southorn V; Folts J J Cardiovasc Pharmacol; 2009 Mar; 53(3):246-52. PubMed ID: 19247190 [TBL] [Abstract][Full Text] [Related]
5. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models. Roux SP; Sakariassen KS; Turitto VT; Baumgartner HR Arterioscler Thromb; 1991; 11(5):1182-91. PubMed ID: 1911705 [TBL] [Abstract][Full Text] [Related]
6. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. Mickelson JK; Hoff PT; Homeister JW; Fantone JC; Lucchesi BR J Am Coll Cardiol; 1993 Feb; 21(2):502-10. PubMed ID: 8426017 [TBL] [Abstract][Full Text] [Related]
7. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Belcher PR; Drake-Holland AJ; Hynd JW; Noble MI Cardiovasc Drugs Ther; 1993 Feb; 7(1):149-57. PubMed ID: 8485070 [TBL] [Abstract][Full Text] [Related]
8. Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. Kirchengast M; Rübsamen K; Lehmann HD J Cardiovasc Pharmacol; 1993 Nov; 22(5):687-94. PubMed ID: 7506319 [TBL] [Abstract][Full Text] [Related]
10. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Demrow HS; Slane PR; Folts JD Circulation; 1995 Feb; 91(4):1182-8. PubMed ID: 7850957 [TBL] [Abstract][Full Text] [Related]
11. Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries. Rovin JD; Stamler JS; Loscalzo J; Folts JD J Cardiovasc Pharmacol; 1993 Oct; 22(4):626-31. PubMed ID: 7505366 [TBL] [Abstract][Full Text] [Related]
12. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. Hsieh CP; Sakai K; Bruns GC; Dage RC J Cardiovasc Pharmacol; 1994 Nov; 24(5):761-72. PubMed ID: 7532754 [TBL] [Abstract][Full Text] [Related]
13. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Yao SK; Ober JC; McNatt J; Benedict CR; Rosolowsky M; Anderson HV; Cui K; Maffrand JP; Campbell WB; Buja LM Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687 [TBL] [Abstract][Full Text] [Related]
14. Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model. Huang J; Rebello SS; Rosenberg LA; Kaneko M; Sakurama T; Lucchesi BR Eur J Pharmacol; 1999 Feb; 366(2-3):203-13. PubMed ID: 10082201 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin. Torr S; Noble MI; Folts JD Cardiovasc Res; 1990 Jun; 24(6):465-70. PubMed ID: 2117499 [TBL] [Abstract][Full Text] [Related]
16. Effects of 3-methoxycyproheptadine in a canine model of coronary thrombosis. Bush LR; Remy DC J Pharmacol Exp Ther; 1988 Nov; 247(2):796-802. PubMed ID: 3183974 [TBL] [Abstract][Full Text] [Related]
17. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries. Bush LR J Pharmacol Exp Ther; 1987 Feb; 240(2):674-82. PubMed ID: 3806419 [TBL] [Abstract][Full Text] [Related]
18. Effect of molsidomine on thrombus formation in stenosed coronary arteries of dogs and pigs. Just M; Martorana PA J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S129-36. PubMed ID: 2484691 [TBL] [Abstract][Full Text] [Related]
19. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Strony J; Phillips M; Brands D; Moake J; Adelman B Circulation; 1990 Mar; 81(3):1106-14. PubMed ID: 2306818 [TBL] [Abstract][Full Text] [Related]